Skip to main content

Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System

NCI - National Cancer Institute

open
OpenLast verified: 2026-07-14

About This Grant

PROJECT SUMMARY/ABSTRACT A lack of proven interventions to prevent leukemia in aged populations leaves a growing demographic vulnerable to this devastating disease. While leukemic cells are subject to immune selection which influences disease progression, we lack knowledge of the stages at which T cells shape the hematopoietic stem and progenitor cell (HSPC) pool from the initiation of clonal hematopoiesis (CH) through to the progression to leukemia, which limits our ability to intervene in this process. The long-term goal of this project is to identify immuno-preventative strategies to intercept leukemogenesis at its earliest stages. The overall objective of this application is to determine the mechanisms by which, and at which stages of pre- leukemic development, HSPC clones are detected and selected by the adaptive immune system. The central hypothesis is that reduced IFNγ responsiveness enables immune evasion of CH-mutant (Dnmt3amut) HSPCs thereby promoting clonal expansion and pre-leukemic evolution. The rationale is grounded in the observation that HSPCs from humans and mice with recurrent CH driver mutations in Dnmt3a have reduced transcript and protein expression of MHC-II machinery, and reduced presentation of exogenous and endogenous antigens via MHC-II. Mechanistically, MHC-II is potently induced by IFNγ on wild-type HSPCs but to a lesser extent on Dnmt3amut HSPCs. In vitro and in vivo, we observe less activation and proliferation of CD4+ T cells by Dnmt3amut HSPCs compared to control HSPCs, supporting that Dnmt3amut HSPCs have reduced immunogenicity. The central hypothesis will be tested by pursuing two specific aims: 1) to define the stages of pre-leukemic HSPC selection that are controlled by CD4+ T cells, and 2) to evaluate decreased IFNγ response of pre-leukemic Dnmt3amut HSPCs as a mechanism of immune evasion. This research is innovative because it introduces a novel framework for understanding how adaptive immunity shapes clonal evolution of pre-leukemic HSPCs. While considerable attention has been given to genetic and cell-intrinsic drivers of CH, the role of immune surveillance—particularly adaptive immune selection—in governing HSPC clonality remains largely unexplored. Ultimately, the proposed work is significant because it will define the role of CD4⁺ T cells in HSPC clone selection during early disease phases in CH and pre-leukemia which has major therapeutic implications for immunoprevention of leukemia.

Grant Summary

Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System is a NCI - National Cancer Institute grant providing up to $705K for university, nonprofit, healthcare org. Applications are due 2031-04-30 (open). Check eligibility and apply with FindGrants.

Not quite the right fit?

Search 9,000+ open grants, or get matches ranked for your organization — free.

Focus Areas

health research

Eligibility

universitynonprofithealthcare org

How to Apply

Funding Range

Up to $705K

Deadline

2031-04-30

Complexity
High
  1. 1Confirm your organization is eligible for Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
  2. 2Gather the required documents and information, including your organization details, project plan, and budget figures.
  3. 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
  4. 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
This record is a past award, contract, or funder profile — useful for research, but not an open grant application. Check the original source for current opportunities from this funder.

Don't want to draft it yourself?

We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.

AI Requirement Analysis

Detailed requirements not yet analyzed

Have the NOFO? Paste it below for AI-powered requirement analysis.

0 characters (min 50)

Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System: Frequently Asked Questions

Who is eligible for the Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System?

Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.

How much funding does the Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System provide?

Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System provides up to $705K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.

When is the Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System deadline?

Applications for Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System are due 2031-04-30 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.

How do you apply for the Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System?

To apply for Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.